- Home
- IBIO vs CDIO Comparison
IBIO vs CDIO Comparison
Compare IBIO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- CDIO
- Stock Information
- Founded
- IBIO 2008
- CDIO 2017
- Country
- IBIO United States
- CDIO United States
- Employees
- IBIO N/A
- CDIO N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- IBIO Health Care
- CDIO Health Care
- Exchange
- IBIO Nasdaq
- CDIO Nasdaq
- Market Cap
- IBIO 9.3M
- CDIO 19.5M
- IPO Year
- IBIO N/A
- CDIO N/A
- Fundamental
- Price
- IBIO $0.77
- CDIO $0.19
- Analyst Decision
- IBIO Strong Buy
- CDIO Buy
- Analyst Count
- IBIO 3
- CDIO 1
- Target Price
- IBIO $4.87
- CDIO $2.00
- AVG Volume (30 Days)
- IBIO 2.2M
- CDIO 1.2M
- Earning Date
- IBIO 05-02-2025
- CDIO 05-23-2025
- Dividend Yield
- IBIO N/A
- CDIO N/A
- EPS Growth
- IBIO N/A
- CDIO N/A
- EPS
- IBIO N/A
- CDIO N/A
- Revenue
- IBIO $375,000.00
- CDIO $34,890.00
- Revenue This Year
- IBIO $36.00
- CDIO $1,434.82
- Revenue Next Year
- IBIO $33.33
- CDIO $4,661.91
- P/E Ratio
- IBIO N/A
- CDIO N/A
- Revenue Growth
- IBIO 650.00
- CDIO 104.45
- 52 Week Low
- IBIO $0.64
- CDIO $0.19
- 52 Week High
- IBIO $6.89
- CDIO $1.77
- Technical
- Relative Strength Index (RSI)
- IBIO 23.90
- CDIO 30.27
- Support Level
- IBIO $0.76
- CDIO $0.39
- Resistance Level
- IBIO $0.89
- CDIO $0.48
- Average True Range (ATR)
- IBIO 0.17
- CDIO 0.06
- MACD
- IBIO 0.11
- CDIO -0.02
- Stochastic Oscillator
- IBIO 13.60
- CDIO 1.27
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.